Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.
about
Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Estimation of drug cost avoida ...... III clinical trials in Canada.
@ast
Estimation of drug cost avoida ...... III clinical trials in Canada.
@en
type
label
Estimation of drug cost avoida ...... III clinical trials in Canada.
@ast
Estimation of drug cost avoida ...... III clinical trials in Canada.
@en
prefLabel
Estimation of drug cost avoida ...... III clinical trials in Canada.
@ast
Estimation of drug cost avoida ...... III clinical trials in Canada.
@en
P2093
P2860
P356
P1433
P1476
Estimation of drug cost avoida ...... III clinical trials in Canada.
@en
P2093
C J O'Callaghan
C R Chambers
N B Leighl
N Mittmann
P2860
P304
P356
10.3747/CO.23.2861
P433
P577
2016-02-29T00:00:00Z